Mounjaro and Trulicity are two injectable medications that treat type 2 diabetes. Learn more about their key similarities, ...

Semaglutide and tirzepatide were the least cost-effective of four obesity drugs examined in a microsimulation model. A multifaceted approach is needed to reduce financial barriers to obesity ...

Tirzepatide is hugely important for Lilly, as its once-weekly GLP-1 agonist for diabetes – Trulicity (dulaglutide) – will start losing patent protection in 2027 and is already feeling pressure ...

Tirzepatide combined with lifestyle modification reduced the highest number of obesity cases (45,609 per 100,000 eligible individuals), diabetes cases (20,854 per 100,000 eligible individuals ...

Eli Lilly's tirzepatide has been shown to significantly cut cardiovascular risks in patients with obesity and a form of heart failure with few treatment options, in another big win for the GLP-1 ...

As a result, there is limited availability of several doses of Mounjaro® (tirzepatide), Zepbound® (tirzepatide) and Trulicity® (dulaglutide) in the U.S,” a spokesperson for Eli Lilly told The ...

In one of the first real-world studies, Tirzepatide shows impressive weight loss results for people without diabetes—shedding nearly 13% of body weight in just six months. Study: Real-world use ...

The FDA announced a similar policy for pharmacies making tirzepatide compounds when ... FDA notes that some other products – including dulaglutide injections sold under the brand name Trulicity ...